Invention Grant
US09580511B2 Site-specific antibody-drug conjugation through glycoengineering
有权
通过糖工程的位点特异性抗体 - 药物共轭
- Patent Title: Site-specific antibody-drug conjugation through glycoengineering
- Patent Title (中): 通过糖工程的位点特异性抗体 - 药物共轭
-
Application No.: US14203479Application Date: 2014-03-10
-
Publication No.: US09580511B2Publication Date: 2017-02-28
- Inventor: Clark Pan , Qun Zhou , James Stefano , Pradeep Dhal , Bo Chen , Diego Gianolio , Robert Miller , Huawei Qiu
- Applicant: Genzyme Corporation
- Applicant Address: US MA Cambridge
- Assignee: GENZYME CORPORATION
- Current Assignee: GENZYME CORPORATION
- Current Assignee Address: US MA Cambridge
- Agency: Lathrop & Gage LLP
- Agent James H. Velema, Esq.
- Main IPC: A61K38/00
- IPC: A61K38/00 ; C07K16/28 ; A61K47/48 ; C07K16/32 ; C07K16/40

Abstract:
The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
Public/Granted literature
- US20140294867A1 SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING Public/Granted day:2014-10-02
Information query
IPC分类: